Assessment of a PstI polymorphism of the apolipoprotein-AI gene in Australian patients with coronary artery disease.
In 1986 Ordovas et al., reported that a polymorphism in the 3' flanking region of the apolipoprotein AI gene was strongly associated with premature coronary artery disease. This polymorphism affects a restriction site for the endonuclease PstI, resulting in the identification of a 3.3 kb band, rather than the more common 2.2 kb band, when genomic blots of PstI digested human DNA are probed with an apolipoprotein AI gene probe. In a study population of 88 patients with severe coronary artery disease before the age of 60, 28 (32%) carried the 3.3 kb allele, which was found in only five (4%) of 123 randomly chosen control subjects. In the present study, we have assessed the prevalence of this polymorphism in coronary artery disease patients and outpatients with abnormal lipid levels at the Alfred Hospital, Melbourne, and in normal volunteers. The 3.3 kb allele was present in 7-12% of subjects in these populations, and showed no association with coronary artery disease.
Dorow
D S
DS
Monash University Department of Pathology and Immunology, Vic.
Burke
J
J
Goding
J W
JW
D000368:Aged; D000483:Alleles; D016632:Apolipoprotein A-I; D001054:Apolipoproteins A / Q000235:genetics*; D003327:Coronary Disease / Q000235:genetics*; D015342:DNA Probes; D015252:Deoxyribonucleases, Type II Site-Specific; D006801:Humans; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012307:Risk Factors
D016632:Apolipoprotein A-I; D001054:Apolipoproteins A; D015342:DNA Probes; C024388:CTGCAG-specific type II deoxyribonucleases; D015252:Deoxyribonucleases, Type II Site-Specific